Monte Rosa Reports Data From GFORCE-1, Phase 1 Study Evaluating MRT-8102, NEK7-Directed MGD Being Developed For Treatment Of Inflammatory Conditions Driven By NEK7/NLRP3 Pathway

Benzinga

2026.10.01 11:15 (GMT+0)

Ouvrir sur Benzinga